Mutational activation of the MAP3K8 protooncogene in lung cancer

Genes Chromosomes and Cancer

Volumn 41, Issue 2, 2004, Pages 99-108

  Clark, Adam Michael ^a,b   Reynolds, Steven H ^c   Anderson, Marshall ^b   Wiest, Jonathan S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MALIGNANT TRANSFORMATION; MAP3K8 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTO ONCOGENE; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR XENOGRAFT;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; RATS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 4143062439     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20069     Document Type: Article

References (33)

1. Aoki M, Akiyama T, Miyoshi J, Toyoshima K. 1991. Identification and characterization of protein products of the cot oncogene with serine kinase activity. Oncogene 6:1515-1519.
2. Aoki M, Hamada F, Sugimoto T, Sumida S, Akiyama T, Toyoshima K. 1993. The human cot proto-oncogene encodes two protein serine/threonine kinases with different transforming activities by alternative initiation of translation. J Bio Chem 268:22723-22732.
3. Bansal A, Ramirez RD, Minna JD. 1997. Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene 14:1231-1234.
4. Beinke S, Dekas J, Belich M, Walker P, Howell S, Smerdon S, Gamblin S, Ley S. 2003. NF-kB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol 23:4739-4752.
5. Belich M, Salmeron A, Johnston L, Ley S. 1999. Tpl-2 kinase regulates the proteolysis of the NF-kB inhibitory protein NF-kB1 p105. Nature 397:363-368.
6. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signaling. Nature 411:355-365.
7. Brognard J, Dennis P. 2002. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Diff 9:893-904.
8. Ceci J, Patriotis C, Tsatsanis C, Makris A, Kovatch R, Swing, D, Jenkins N, Tsichlis P, Copeland N. 1997. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 11:688-700.
9. Chan A, Chedid M, McGovern E, Popescu N, Miki, T, Aaronson S. 1993. Expression cDNA cloning of a serine kinase transforming gene. Oncogene 8:1329-1333.
10. Chiariello M, Marinissen M, Gutkind J. 2000. Multiple mitogen-activated signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20: 1747-1758.
11. Dumitru C, Ceci J, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin J, Patriotis C, Jenkins N, Copeland N, Kollias G, Tsichlis P. 2000. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103:1071-1083.
12. Eliopoulos A, Davies C, Blake S, Murray P, Najafipour S, Tsichlis P, Young L. 2002. The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus encoded latent infection membrane protein 1-induced NF-kB signaling downstream of TRAF2. J Virol 76:4567-4579.
13. Eliopoulos A, Wang C, Dumitru C, Tsichlis P. 2003. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 22:3855-3864.
14. Fasano O, Birnbaum D, Edlund L, Fogh J, Wigler M. 1984. New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol 4:1695-1705.
15. Ghosh S, May M, Kopp E. 1998. NF-kB and rel proteins: evolutionarity conserved mediators of immune response. Annu Rev Immunol 16:225-260.
16. Hagemann D, Troppmair J, Rapp U. 1999. Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells. Oncogene 18:1391-1400.
17. Harris B, Lim W. 2001. Mechanism and role of PDZ domains in signaling complex assembly. J Cell Sci 114:3219-3231.
18. Janulis M, Silberman S, Ambegaokar A, Gutkind J, Schultz R. 1999. Role of mitogen-activated protein kinases and c-Jun/AP-1 transactivating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. J Biol Chem 274: 801-813.
19. Jones D, Broad M, Madrid L, Baldwin A, Mayo M. 2000. Inhibition of NF-kB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Soc Thorac Surg 70:930-937.
20. Kane L, Mollenauer M, Xu Z, Turck C, Weiss A. 2002. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kB-dependent transcription. Mol Cell Biol 22:5962-5974
21. Kondo M, Osada H, Uchida K, Yanagisawa K, Masuda A, Takagi K, Takahashi T, Takahashi T. 1998. Molecular cloning of the human Tak1 gene and its mutational analysis in human lung cancer. Int J Cancer 75:559-563.
22. Lin X, Cunningham E, Mu Y, Geleziunas R, Greene W. 1999. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kB acting through the NF-kB-inducing kinase and IkB kinases. Immunity 10:271-280.
23. Makris A, Patriotis C, Bear S, Tsichlis P. 1993. Genomic organization and expression of Tpl-2 in normal cells and Moloney Murine Leukemia Virus-induced rat T-cell lymphomas: activation by provirus insertion. J Virol 67:4283-4289.
24. Miwa W, Yasuda J, Yashima K, Makino R, Sekiya T. 1994. Absence of activating mutations of the Raft protooncogene in human lung cancer. Biol Chem Hoppe-Seyler 375:705-709.
25. Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T. 1991. Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11:4088-4096.
26. Patriotis C, Makris A, Bear S, Tsichlis P. 1993. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in T-cell lymphomas and in T-cell activation. Proc Nat Acad Sci USA 90:2251-2255.
27. Patriotis C, Makris A, Chernoff J, Tsichlis P. 1994. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc Natl Acad Sci USA 91:9755-9759.
28. Reynolds SH, Anna CK, Brown KC, Wiest JS, Beattie EJ, Pero RW, Iglehart JD, Anderson MW. 1991. Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA 88: 1085-1089
29. Salmeron A, Ahmad T, Carlile G, Pappin D, Narsimhan R, Ley S. 1996. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO 15:817-826.
30. Sekido Y, Fong K, Minna J. 1998. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378:F21-F59.
31. Sourvinos G, Tsatsanis C, Spandidos D. 1999. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18:4968-4973.
32. Tsatsanis C, Patriotis C, Tsichilis P. 1998. Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kB. Oncogene 17:2609-2618.
33. Waterfield M, Zhang M, Norman L, Sun S. 2003. NF-kB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell 11:685-694.